Advancing Knowledge and Thought Leadership


Researchers at Boston Health Economics, the Carolina Urologic Research Center, and Janssen, also found high hospitalization rates associated with metastatic prostate cancer.

WALTHAM, MA, September 15, 2017 –—A new study shows that the development of prostate cancer metastasis was associated with a five-fold increase in medical costs at the time of diagnosis, and substantially higher costs thereafter. Published in the May issue of Cancer, the scientific journal of the American Cancer Society, the study, titled “Impact of Subsequent Metastases on Costs and Medical Resource Use for Prostate Cancer Patients Initially Diagnosed with Localized Disease,” was conducted by BHE, the Carolina Urologic Research Center (CURC), and Janssen. Cancer also published an editorial by Drs. Daniel Frendl and Aria Olumi that discusses the value of this study’s data in the same issue of the journal.  

The study, led by Drs. Tracy T. Li, PhD (Janssen), Neal D. Shore, MD, FACS (CURC), and Robert I. Griffiths, MS, ScD (BHE & Oxford University), utilized US national cancer registry data linked to Medicare insurance claims to evaluate a large population of men diagnosed with localized prostate cancer. 

“In this study we were able to show that as the prostate cancer progresses, there are detrimental events not only clinically but also economically associated with metastatic disease.” stated Dr. Tracy Li, lead author of the study and Director of Health Economics and Market Access at Janssen.

Li et al found that almost half of the patients (48.6%) in the metastatic group required at least one inpatient admission around the time of diagnosis. In addition, utilization of outpatient resources also increased from 19% to 54% among patients in the metastatic group.

According to Dr. Neal Shore, Medical Director for the CURC, who has conducted over 250 clinical trials in genitourinary oncology, this study represents “the largest analysis of this population, and clearly demonstrates there is an unmet clinical need for intervention before metastatic disease diagnosis, as well as a significant economic impact for healthcare systems.”

About the Study:

Investigators at BHE, the CURC, and Janssen collaborated on the study, “Impact of Subsequent Metastases on Costs and Medical Resource Use for Prostate Cancer Patients Initially Diagnosed with Localized Disease.” Key investigators and their roles are listed below:

  • Neal D. Shore, MD, FACS, at CURC: Senior clinical investigator responsible for design shape and study implementation, as well as framing and interpretation of results.
  • Tracy T. Li, PhD at Janssen: Co-investigator responsible for the design shape and study implementation, as well preparing the findings for publication.
  • Robert I. Griffiths at BHE: Co-investigator responsible for overall study design, implementation, and reporting of results.

About BHE:

With over 20 years of impactful real world evidence (RWE) results, Boston Health Economics (BHE) continues to advance and innovate healthcare analytics research through technology-enabled, analytic solutions. BHE leverages cutting-edge data sources, expert methodological and clinical staff, and its proprietary technology solution, Instant Health Data, to quickly deliver actionable results to stakeholders across the healthcare industry. For more information, please follow us on LinkedIn and Twitter.

About Carolina Urologic Research Center:

Carolina Urologic Research Center (CURC), is a separate and independent research arm of Grand Strand Urology, a division of Atlantic Urology Clinics in Myrtle Beach, SC. Under the direction of Dr. Neal Shore, CURC conducts phase I – IV drug, biotechnology and device trials focusing on urological diseases. CURC has been recognized both nationally & internationally as one of the most progressive, well-organized, and respected clinical research sites in the United States.


If you would like more information about this topic, please call Patricia Dickerson at 781-290-0808 or email

View press release on PRWeb:

September 15, 2017 Waltham, MA

BHE is headed to Philly for the 2nd Real World Data for Competitive Advantage Summit.

Join us at the Real World Data for Competitive Advantage Summit in Philadelphia! For more information or to schedule at time with our team, please reach out to Jack Fuller.

December 4 - 5, 2017 Sheraton Philadelphia University City Hotel, Philadelphia, PA

Join us in Baltimore for ISPOR's 23rd Annual International Meeting!

ISPOR's 23rd Annual Meeting is in Baltimore, MD! If you are interested in setting up a specific time to meet with us, please reach out to Jack Fuller.

May 19-23, 2018 Baltimore Convention Center, Baltimore, MD

Filter By


Cost-effectiveness analysis of vagal nerve blocking for morbid obesity

American Journal of Managed Care, 2017; 23 (8): 245-252. Jeffrey C. Yu, AB, Bruce Wolft, MD, Robert I. Griffiths, ScD, MS, Raul Rosenthal, MD, Daniel Cohen, MA, and Iris Lin, PhD.

Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs.

BMC Neurology. 2017 Jun 5;17:106 Michael Munsell, Molly Frean, Jospeh Menzin, Amy L.Phillips

Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease

Cancer, 23 May 2007 Tracy T. Li PhD, Neal D. Shore MD, Maneesha Mehra MPH, Mary B. Todd MD, Ryan Saadi MD, Gaetan Leblay MBA, Jyoti Aggarwal MHS, Robert I. Griffiths MS, ScD
Mental Health

Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder

Journal of Affective Disorders, 2017 Jan 1;207:54-62. Matthew Sussman, Jeffrey Yu, Siddhesh A Kamat, Ann Hartry, Susan Legacy, Ruth Duffy, Myrlene Sanon Aigbogun

An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug

Patient Preference and Adherence, 2016 Dec 11:55-62 Michael Munsell, Molly Frean, Joseph Menzin, Amy L. Phillips

Economic impact of hypoglycemia among insulin-treated patients with diabetes

Journal of Medical Economics, 2016 Nov;19(11):1099-1106. Matthew Sussman, MA, Joseph A. Sierra, BA, Satish Garg, MD, Bruce Bode, MD, Mark Friedman, MD, Max Gill, MBA, Francine Kaufman, MD, Robert Vigersky, MD, Joseph Menzin, PhD

Resource use among nonvalvular atrial fibrillation patients

American Journal of Pharmacy Benefits, 2016;8(5):84-92. Sussman M, Ghate S, Sutherland S, Wang C, Sander S, Griffiths R.

Patterns of statin use in a real-world population of patients at high cardiovascular risk

Journal of Managed Care & Specialty Pharmacy, 2016 Jun;22(6):685-98 Lin I, Sung J, Sanchez R, Mallya U, Friedman M, Panaccio M, Koren A, Neumann P, Menzin J

Economic evaluation of linaclotide for the treatment of adult patients with chronic idiopathic constipation in the United States

Journal of Managed Care, 2016 Feb;25(2):41-8. Huan Huang, PhD; Douglas C.A. Taylor, MBA; Robyn T. Carson, MPH; Phil Sarocco, RPh, MSc; Mark Friedman, MD; Michael Munsell, BA; Steven I. Blum, MBA, MA; Joseph Menzin, PhD

Antithrombotic use and bleeding risk in patients with atrial fibrillation: findings from a multi-payer analysis.

Journal of Comparative Effectiveness Research, 2016 Jan;5(1):39-48. Lang K, Federico V, Patel AA, Munsell M, Nelson WW, Owens G, Mody SH, Schein J, Menzin J

Let's Connect!

Schedule a Meeting